Elanco completed the acquisition of Kindred BioSciences on August 30, 2021. The acquisition expands our existing relationship, enabling us to maximize the impact of our R&D pipeline, bring innovative solutions to veterinarians and pet owners in areas of unmet or under-served medical needs, and ultimately, advance our shared vision of improving the lives of pets. You can find more information here.
Effective January 15, 2022, Kindred Biosciences suppliers will transition to Elanco processes and systems. Click here for an overview of changes.
For questions or help with: